Actively Recruiting
Evaluating Duvelisib as Maintenance Therapy After Initial Treatment for Peripheral T-Cell Lymphoma
Led by City of Hope Medical Center · Updated on 2026-10-19
25
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating duvelisib as a maintenance treatment for patients with peripheral T-cell lymphomas who have achieved a complete response after initial therapy but cannot or choose not to undergo stem cell transplantation. This phase II trial aims to determine how well duvelisib works to prevent cancer from returning and to assess its tolerability and survival outcomes. The study also explores the relationship between biomarkers, such as minimal residual disease, and clinical outcomes like response rates and progression-free survival. Participants receive oral duvelisib twice daily for 28-day cycles, continuing up to one year unless the disease progresses or side effects become unacceptable. Those in continuous complete response may extend treatment for an additional 13 cycles. Throughout the study, patients undergo bone marrow aspiration and biopsy during screening and may have these procedures repeated. Imaging with PETCT scans and blood sample collections occur regularly during the trial. After finishing treatment, participants are followed up 4 to 6 weeks later and then periodically for up to five years. The study includes various assessments such as scans, laboratory tests, and patient surveys to monitor progress and side effects. The primary outcome measured is progression-free survival at one year, with secondary outcomes including treatment tolerability, patient-reported outcomes, time to next therapy, overall survival, and longer-term progression-free survival.
CONDITIONS
Brief Title
Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here